Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.

Authors: Yun Xu, Yuchen Wu, Yuedi Dai, Xiaopin Ji, Zhe Cui, Xiaodong Zhu, Ye Xu

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.151

Source: Full article

151